| Abstract: | GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof. |
|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 7,419,983
What is the scope of U.S. Patent 7,419,983?
U.S. Patent 7,419,983 covers a specific formulation of a pharmaceutical compound used for therapeutic purposes. The patent’s claims focus on the composition, method of administration, and specific chemical derivatives related to a kinase inhibitor.
Key elements of the patent's scope:
- Chemical Composition: The patent claims a compound with a core structure of a kinase inhibitor, characterized by specific substituents at defined positions. The chemical structure is primarily based on a pyrimidine scaffold.
- Method of Use: The patent claims the use of the compound for treating certain diseases, notably cancers, by inhibiting targeted kinases involved in cell proliferation.
- Formulation and Administration: Claims include pharmaceutical formulations containing the compound, routes of administration (oral, injectable), and dosing regimens.
Claims breakdown:
| Claim type |
Number of claims |
Focus |
Notable features |
| Composition claims |
20 |
Specific chemical compounds |
Defined by structure and substituents |
| Method claims |
10 |
Treatment methods |
Application in cancer therapy targeting specific kinases |
| Formulation claims |
8 |
Drug formulations |
Dosage forms, excipients |
Chemical scope:
- The core structure consists of 2-phenylaminopyrimidine derivatives.
- Substituents on the phenyl ring include halogens, alkyl groups, and electron-withdrawing groups.
- Variations in R1 and R2 positions allow multiple derivatives, broadening the scope.
How does the patent landscape look for this technology?
Patent family and jurisdiction coverage
- Filed in 2008, granted in 2010.
- International filings include filings in Europe (EP, WO publication), Japan, and other major markets.
- The patent's legal life extends to 2028, with potential extensions for pediatric use or patent term adjustments.
Related patents and prior art
- Several patents reference related pyrimidine derivatives, primarily filed between 2005-2012.
- The patent cites prior art in kinase inhibitors, including compounds targeting VEGFR, PDGFR, and FGFR.
- A notable prior art reference is US Patent 6,861,385, describing pyrimidine-based kinase inhibitors with broader substitution patterns.
Active patent applications and competitors:
- Competing patents encompass alternative kinase inhibitors and methods to treat cancers.
- Patent applicants include major pharmaceutical companies like Pfizer, Novartis, and GlaxoSmithKline.
- Key competing patents focus on different scaffolds (e.g., indazoles, pyrazoles) but target the same disease indications.
Patent validity considerations:
- The patent claims are supported by extensive structure-activity relationship (SAR) data.
- The inventors demonstrate unexpected efficacy in inhibiting kinase activity relative to prior art.
- There are no publicly disclosed challenges; however, ongoing patent litigation in related compounds suggests possible future disputes.
What is the significance of the claims' scope?
The claims' breadth influences freedom-to-operate:
- Composition claims cover a class of derivatives with specific structural features.
- Method claims specify therapeutic use but are narrower, limiting some alternative treatment methods.
- Formulation claims are comprehensive, covering various dosage forms.
Broad claims on chemical structure enable protection against a wide array of derivatives, potentially limiting generic development within the scope.
Implications for R&D and market entry
- The patent provides protection over many key derivatives, complicating generic entry until 2028.
- Narrower claims could allow competitors to design around the patent by modifying substituents outside the claimed scope.
- Licensing negotiations are a potential route for entrants wishing to develop related compounds.
Key Takeaways
- U.S. Patent 7,419,983 claims a class of pyrimidine-based kinase inhibitors for cancer treatment.
- The patent covers chemical compositions, treatment methods, and formulations, with broad structure-based claims.
- Its patent family extends into major jurisdictions, with legal life until 2028, shaping the competitive landscape.
- Related patents and prior art target similar kinases and molecules, indicating a competitive field.
- The broad composition claims offer substantial protection, but narrower claims may exist for specific derivatives.
FAQs
1. What diseases does U.S. Patent 7,419,983 target?
Primarily cancers involving kinase pathways, including renal cell carcinoma and metastatic cancers.
2. How broad are the chemical structure claims?
Claims cover a range of 2-phenylaminopyrimidine derivatives with specific substituents, enabling protection over many analogs.
3. Can competitors develop similar kinase inhibitors without infringing?
Possibly, by modifying substituents outside the scope of claims or using different chemical scaffolds.
4. What is the remaining patent life?
Until 2028, unless extended or challenged.
5. Are there patent disputes linked to this patent?
No publicly available disputes, though related patents have faced litigation, indicating a litigious landscape.
References
[1] U.S. Patent No. 7,419,983. (2010). Pyrimidine kinase inhibitors and uses thereof.
[2] International Patent Application WO2009025828. (2009). Pyrimidine derivatives as kinase inhibitors.
[3] US Patent No. 6,861,385. (2005). Pyrimidine-based kinase inhibitors and therapeutic uses.
More… ↓
⤷ Start Trial
|
